Ventyx Biosciences has completed the enrolment of patients in the Phase II trial of VTX002 in ulcerative colitis and SERENITY trial of VTX958 in plaque psoriasis.

The placebo-controlled, randomised, double-blind study of VTX002 has enrolled around 180 patients with moderately to severely active ulcerative colitis. They will be randomised to receive one of two doses of VTX002 against placebo in an induction treatment period of 13 weeks.

They will be followed by a blinded long-term extension period of 39 weeks.

Proportion of patients achieving clinical remission at week 13, as defined by the modified Mayo Score, is the primary efficacy endpoint.

Ventyx has enrolled nearly 200 patients with moderate to severe plaque psoriasis in the dose-ranging, double-blind, placebo-controlled, randomised Phase II SERENITY trial.

Patients will be randomised to receive one of four VTX958 doses against placebo in a 16-week treatment period which will followed by a blinded long-term extension period of the same duration.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Proportion of subjects achieving a reduction of 75% in the Psoriasis Area and Severity Index (PASI 75) at week 16 is the primary efficacy endpoint.

Ventyx Biosciences president and chief medical officer Dr William Sandborn said: “We believe the robust enrolment activity in these trials demonstrates tremendous interest from patients and investigators in novel oral therapies for autoimmune diseases.”

Topline results from both the trials are expected in the fourth quarter of this year.

Ventyx is also continuing enrolment in Phase II HARMONY trial of VTX958 in patients with moderately to severely active Crohn’s disease and Phase II trial in active psoriatic arthritis. Topline results from the trials are anticipated next year.